Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARQT trades at $20.80 with a market cap of $2.51B and a P/E ratio of -676.83. ARQT moved +5.00% today. Year to date, ARQT is -32.22%; over the trailing twelve months it is +41.08%. Its 52-week range spans $8.03 to $31.77. Analyst consensus is strong buy with an average price target of $34.63. Rallies surfaces ARQT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes ARQT SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $20.80 |
| Market Cap | $2.51B |
| P/E Ratio | -676.83 |
| EPS | $-0.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.77 |
| 52-Week Low | $8.03 |
| Volume | 821 |
| Avg Volume | 0 |
| Revenue (TTM) | $415.62M |
| Net Income | $-2.38M |
| Gross Margin | 90.94% |
8 analysts cover ARQT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.63.